The Latest, Most Promising Treatments
If you’ve been diagnosed with MDS, you can’t wait six to 12 months for the FDA to approve a drug. You need it now. Our goal is to provide our patients with cutting-edge, groundbreaking therapies even before those treatments are widely available.
We offer a wide range of clinical trials of new and promising treatments, including the latest immunotherapies and targeted therapies for patients with MDS and other hematological malignancies (blood cancers).
A Nationally Recognized Expert Who Helps Set the Standards
Elizabeth Griffiths, MD, Roswell Park’s Director of MDS, is among the experts who serve on the National Comprehensive Cancer Network (NCCN) panel that develops the national guidelines for the diagnosis and treatment of MDS.
Fast, Early, Accurate Detection & Diagnosis
Roswell Park’s Pathology team includes hematopathologists, specialists who concentrate on diagnosing blood cancers — nothing but blood cancers — every single day, as part of a dedicated, highly skilled team specializing in the diagnosis of myeloid malignancies such as MDS and other blood cancers.
Our in-house laboratories process our samples quickly and efficiently to determine the best treatment approach — usually within just a few days.
One of the Nation’s Top Centers for Bone Marrow Transplant
A bone marrow transplant (BMT) is the only chance for curing MDS. Our Transplant & Cellular Therapy Center is ranked one of the nation’s best, based on patient survival.
A Specialized Clinical Genetics Service
In some cases, MDS is caused by an inherited disorder, such as Schwachman-Diamond syndrome, familial platelet disorder, severe congenital neutropenia or a rare congenital disease called Fanconi anemia. The formally trained genetic counselors of Roswell Park’s Clinical Genetics Service specialize exclusively in assessing inherited cancer risk.